0001654954-24-000764.txt : 20240119 0001654954-24-000764.hdr.sgml : 20240119 20240119145224 ACCESSION NUMBER: 0001654954-24-000764 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 16 CONFORMED PERIOD OF REPORT: 20240105 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240119 DATE AS OF CHANGE: 20240119 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Healthcare Business Resources, Inc. CENTRAL INDEX KEY: 0001796949 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-MANAGEMENT CONSULTING SERVICES [8742] ORGANIZATION NAME: 07 Trade & Services IRS NUMBER: 843639946 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-56214 FILM NUMBER: 24545272 BUSINESS ADDRESS: STREET 1: 718 THOMPSON LN. STREET 2: SUITE 108-273 CITY: NASHVILLE STATE: TN ZIP: 37204 BUSINESS PHONE: 615-696-7676 MAIL ADDRESS: STREET 1: 718 THOMPSON LN. STREET 2: SUITE 108-273 CITY: NASHVILLE STATE: TN ZIP: 37204 8-K 1 hbr_8k.htm FORM 8-K hbr_8k.htm

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): January 5, 2024

 

Healthcare Business Resources Inc.

 (Exact name of registrant as specified in its charter)

 

Delaware

 

000-56214

 

84-3639946

(State or other jurisdiction of

Incorporation or Organization)

 

(Commission File Number)

 

(I.R.S. Employer

Identification No.)

 

1983 N Berra Blvd, Tooele, Utah

 

84074

(Address of principal executive offices)

 

(Zip Code)

 

Registrant's telephone number, including area code: 615-856-5542

 

                                                                                                             

(Former name or former address, if changed since last report) 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act: None

 

Title of each class

Trading Symbol(s)

Name of exchange on which registered

 

Indicate by check mark whether the registrant is an emerging growth company as defined in in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company

 

If an emerging growth company, indicate by checkmark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 

 

 

 

Item 8.01 Other Events.

 

On January 5, 2024, Healthcare Business Resources Inc. (the “Company”) entered into a consulting agreement with Alex Bellehumeur for management and board consultancy matters. Mr. Bellehumeur, through Contained Resources, LLC, is a 20.07% owner of the Company. A copy of the consulting agreement is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

 

Item 9.01 Financial Statements and Exhibits

 

(d) Exhibits

 

Exhibit No.

 

Description

99.1

 

Consulting Agreement - Alex Bellehumeur dated 01/05/2024

104

 

Cover Page Interactive Data File (formatted as Inline XBRL)

 

 
2

 

 

SIGNATURES

 

                Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

HEALTHCARE BUSINESS RESOURCES INC.

 

 

 

 

 

 

By:

/s/ Drew D. Hall

 

 

Name:

Drew D. Hall

 

 

Title:

Chief Executive Officer and Chief Financial Officer

 

 

Dated: January 19, 2024

 

 
3

 

EX-99.1 2 hbr_ex991.htm CONSULTING AGREEMENT hbr_ex991.htm

  EXHIBIT 99.1

 

 

January 5, 2024

 

Alex Bellehumeur

6242 Napoli CT.

Long Beach, CA 90803

 

Dear Alex,

 

This letter agreement (this "Agreement") sets forth the terms and conditions whereby you agree to provide certain consulting services (as described in Schedule 1) to Healthcare Business Resources Inc., a Delaware corporation (the "Company"), with offices located at 1983 N Berra Blvd, Tooele, Utah 84074.

 

1. Services.

 

1.1 The Company engages you, and you accept such engagement, as an independent contractor to provide certain services to the Company on the terms and conditions set forth in this Agreement.

 

1.2 You shall provide to the Company the services listed on Schedule 1 (the "Services").

 

1.3 The Company does not and shall not control or direct the manner or means by which you perform the Services, including but not limited to, the time and place you perform the Services. You will perform work that is outside the usual course of the Company's business. You are customarily engaged in an independently established trade, occupation, or business of the same nature as the Services performed.

 

1.4 Unless otherwise stated on Schedule 1, you shall furnish, at your own expense, the materials, equipment, supplies, and other resources necessary to perform the Services. The Company shall provide you with access to its premises, materials, information, and systems to the extent necessary for the performance of the Services.

 

1.5 You shall comply with all third-party access rules and procedures communicated to you in writing by the Company, including those related to safety, security, and confidentiality.

 

2. Term. The term of this Agreement shall commence as of the date set forth above and shall continue for a period of 12 months, unless earlier terminated in accordance with Section 10 (the "Term"). Any extension of the Term will be subject to mutual written agreement between you and the Company (referred to collectively as the "Parties").

 

 

 

 

3. Fees and Expenses.

 

3.1 As full compensation for the Services and the rights granted to the Company in this Agreement, the Company shall pay you the fixed fee (the "Fees") set forth on Schedule 1. You acknowledge that you will receive an IRS Form 1099-NEC from the Company, and that you shall be solely responsible for all federal, state, and local taxes, as set out in Section 4.2.

 

3.2 You will be reimbursed for any travel or other costs or expenses incurred by you in connection with the performance of the Services that have been approved in advance in writing by the Company.

 

3.3 The Company shall pay all undisputed Fees within 10 business days after the Company's receipt of an invoice submitted by you.

 

4. Relationship of the Parties.

 

4.1 You are an independent contractor of the Company, and this Agreement shall not be construed to create any association, partnership, joint venture, employment, or agency relationship between you and the Company for any purpose. You have no authority (and shall not hold yourself out as having authority) to bind the Company and you shall not make any agreements or representations on the Company's behalf without the Company's prior written consent.

 

4.2 Without limiting Section 4.1, you will not be eligible to participate in any vacation, group medical or life insurance, disability, profit sharing or retirement benefits, or any other fringe benefits or benefit plans offered by the Company to its employees, and the Company will not be responsible for withholding or paying any income, payroll, Social Security, or other federal, state, or local taxes, making any insurance contributions, including for unemployment or disability, or obtaining workers' compensation insurance on your behalf. You shall be responsible for, and shall indemnify the Company against, all such taxes or contributions, including penalties and interest. Any persons employed or engaged by you in connection with the performance of the Services shall be your employees or contractors, and you shall be fully responsible for them and fully indemnify the Company against any claims made by or on behalf of any such employee or contractor.

 

5. Intellectual Property Rights.

 

5.1 You hereby irrevocably assign to the Company, for no additional consideration, your entire right, title, and interest throughout the world in and to all results and proceeds of the Services performed under this Agreement the deliverables set out in Schedule 1 (collectively, the "Deliverables") and all other writings, technology, inventions, discoveries, processes, techniques, methods, ideas, concepts, research, proposals, and materials, and all other work product of any nature whatsoever, that are created, prepared, produced, authored, edited, modified, conceived, or reduced to practice in the course of performing the Services or other work performed in connection with the Services or this Agreement (collectively, and including the Deliverables, "Work Product"), and all patents, copyrights, trademarks (together with the goodwill symbolized thereby), trade secrets, know-how, and other confidential or proprietary information, and other intellectual property rights (collectively "Intellectual Property Rights") therein, including the right to sue for past, present, and future infringement, misappropriation, or dilution thereof.

 

 
2

 

 

5.2 To the extent any copyrights are assigned under this Section 5, you irrevocably waive in favor of the Company, to the extent permitted by applicable law, any and all claims you may now or hereafter have in any jurisdiction to all rights of paternity or attribution, integrity, disclosure, and withdrawal and any other rights that may be known as "moral rights" in relation to all Work Product to which the assigned copyrights apply.

 

5.3 You shall make full and prompt written disclosure to the Company of any inventions or processes, as such terms are defined in 35 U.S.C. § 100, that constitute Work Product, whether or not such inventions or processes are patentable or protected as trade secrets. You shall not disclose to any third party the nature or details of any such inventions or processes without the prior written consent of the Company. Any patent application for or application for registration of any Intellectual Property Rights in any Work Product that you may file during the Term or at any time thereafter will belong to the Company, and you hereby irrevocably assign to the Company, for no additional consideration, your entire right, title, and interest in and to such application, all Intellectual Property Rights disclosed or claimed therein, and any patent or registration issuing or resulting therefrom.

 

5.4 Upon the reasonable request of the Company, during and after the Term, you shall promptly take such further actions, including execution and delivery of all appropriate instruments of conveyance, and provide such further cooperation, as may be reasonably necessary to assist the Company to apply for, prosecute, register, maintain, perfect, record, or enforce its rights in any Work Product and all Intellectual Property Rights therein. In the event the Company is unable, after reasonable effort, to obtain your signature on any such documents, you hereby irrevocably designate and appoint the Company as your agent and attorney-in-fact, to act for and on your behalf solely to execute and file any such application or other document and do all other lawfully permitted acts to further the prosecution and issuance of patents, copyrights, or other intellectual property protection related to the Work Product with the same legal force and effect as if you had executed them. You agree that this power of attorney is coupled with an interest.

 

5.5 Notwithstanding Section 5.1, to the extent that any of your preexisting materials are incorporated in or combined with any Deliverable or otherwise necessary for the use or exploitation of any Work Product, you hereby grant to the Company an irrevocable, worldwide, perpetual, royalty-free, non-exclusive license to use, publish, reproduce, perform, display, distribute, modify, prepare derivative works based upon, make, have made, sell, offer to sell, import, and otherwise exploit such preexisting materials and derivative works thereof. The Company may assign, transfer, and sublicense (through multiple tiers) such rights to others without your approval.

 

 
3

 

 

5.6 As between you and the Company, the Company is, and will remain, the sole and exclusive owner of all right, title, and interest in and to any documents, specifications, data, know-how, methodologies, software, and other materials provided to you by the Company ("Company Materials"), and all Intellectual Property Rights therein. You have no right or license to reproduce or use any Company Materials except solely during the Term to the extent necessary to perform your obligations under this Agreement. All other rights in and to the Company Materials are expressly reserved by the Company. You have no right or license to use the Company's trademarks, service marks, trade names, logos, symbols, or brand names.

 

5.7 You shall require each of your employees and contractors to execute written agreements containing obligations of confidentiality and non-use and assignment of inventions and other work product consistent with the provisions of this Section 5 prior to such employee or contractor providing any Services under this Agreement.

 

6. Confidentiality.

 

6.1 You acknowledge that you will have access to information that is treated as confidential and proprietary by the Company including, without limitation operations of the Company, its affiliates, or their suppliers or customers, in each case whether spoken, written, printed, electronic, or in any other form or medium (collectively, the "Confidential Information"). Any Confidential Information that you access or develop in connection with the Services, including but not limited to any Work Product, shall be subject to the terms and conditions of this clause. You agree to treat all Confidential Information as strictly confidential, not to disclose Confidential Information or permit it to be disclosed, in whole or part, to any third party without the prior written consent of the Company in each instance, and not to use any Confidential Information for any purpose except as required in the performance of the Services. You shall notify the Company immediately in the event you become aware of any loss or disclosure of any Confidential Information.

 

6.2 Confidential Information shall not include information that:

 

(a) is or becomes generally available to the public other than through your breach of this Agreement; or

 

(b) is communicated to you by a third party that had no confidentiality obligations with respect to such information.

 

6.3 Nothing in this Agreement shall be construed to prevent disclosure of Confidential Information as may be required by applicable law or regulation, or pursuant to the valid order of a court of competent jurisdiction or an authorized government agency, provided that the disclosure does not exceed the extent of disclosure required by such law, regulation, or order. You agree to provide written notice of any such order to an authorized officer of the Company within 3 business days of receiving such order, but in any event sufficiently in advance of making any disclosure to permit the Company to contest the order or seek confidentiality protections, as determined in the Company's sole discretion.

 

 
4

 

 

6.4 Notice of Immunity Under the Defend Trade Secrets Act of 2016 ("DTSA"). Notwithstanding any other provision of this Agreement:

 

(a) You will not be held criminally or civilly liable under any federal or state trade secret law for any disclosure of a trade secret that:

 

(i) is made: (A) in confidence to a federal, state, or local government official, either directly or indirectly, or to an attorney; and (B) solely for the purpose of reporting or investigating a suspected violation of law; or

 

(ii) is made in a complaint or other document that is filed under seal in a lawsuit or other proceeding.

 

(b) If you file a lawsuit for retaliation by the Company for reporting a suspected violation of law, you may disclose the Company's trade secrets to your attorney and use the trade secret information in the court proceeding if you:

 

(i) file any document containing the trade secret under seal; and

 

(ii) do not disclose the trade secret, except pursuant to court order.

 

7. Representations and Warranties.

 

7.1 You represent and warrant to the Company that:

 

(a) you have the right to enter into this Agreement, to grant the rights granted in this Agreement, and to perform fully all of your obligations in this Agreement;

 

(b) your entering into this Agreement with the Company and your performance of the Services do not and will not conflict with or result in any breach or default under any other agreement to which you are subject;

 

(c) you have the required skill, experience, and qualifications to perform the Services, you shall perform the Services in a professional and workmanlike manner in accordance with generally recognized industry standards for similar services, and you shall devote sufficient resources to ensure that the Services are performed in a timely and reliable manner;

 

(d) you shall perform the Services in compliance with all applicable federal, state, and local laws and regulations, including by maintaining all licenses, permits, and registrations required to perform the Services;

 

(e) the Company will receive good and valid title to all Work Product, free and clear of all encumbrances and liens of any kind; and

 

(f) all Work Product is and shall be your original work (except for material in the public domain or provided by the Company) and, to the best of your knowledge, does not and will not violate or infringe upon the intellectual property right or any other right whatsoever of any person, firm, corporation, or other entity.

 

 
5

 

 

7.2 The Company represents and warrants to you that:

 

(a) it has the full right, power, and authority to enter into this Agreement and to perform its obligations hereunder; and

 

(b) the execution of this Agreement by its representative, whose signature is set forth at the end of this Agreement, has been duly authorized by all necessary corporate action.

 

8. Indemnification.

 

8.1 You shall defend, indemnify, and hold harmless the Company and its affiliates and their officers, directors, employees, agents, successors, and assigns from and against all losses, damages, liabilities, deficiencies, actions, judgments, interest, awards, penalties, fines, costs, or expenses of whatever kind (including reasonable attorneys' fees) arising out of or resulting from:

 

(a) bodily injury, death of any person, or damage to real or tangible personal property resulting from your acts or omissions; or

 

(b) your breach of any representation, warranty, or obligation under this Agreement.

 

8.2 The Company may satisfy such indemnity (in whole or in part) by way of deduction from any payment due to you.

 

9. Intentionally Left Blank.

 

10. Termination.

 

10.1 You or the Company may terminate this Agreement without cause upon 30 calendar days' written notice to the other party to this Agreement. In the event of termination pursuant to this clause, the Company shall pay you on a pro-rata basis any Fees then due and payable for any Services completed, up to and including the date of such termination.

 

10.2 You or the Company may terminate this Agreement, effective immediately upon written notice to the other party to this Agreement, if the other party materially breaches this Agreement, and such breach is incapable of cure, or with respect to a material breach capable of cure, the other party does not cure such breach within 10 business days after receipt of written notice of such breach.

 

10.3 Upon expiration or termination of this Agreement for any reason, or at any other time upon the Company's written request, you shall promptly after such expiration or termination:

 

(a) deliver to the Company all Deliverables (whether complete or incomplete) and all materials, equipment, and other property provided for your use by the Company;

 

 
6

 

 

(b) deliver to the Company all tangible documents and other media, including any copies, containing, reflecting, incorporating, or based on the Confidential Information;

 

(c) permanently erase all of the Confidential Information from your computer and phone systems; and

 

(d) certify in writing to the Company that you have complied with the requirements of this clause.

 

10.4 The terms and conditions of this clause and Section 4, Section 5, Section 6, Section 7, Section 8, Section 11, Section 13, Section 14, Section 16, and Section 17 shall survive the expiration or termination of this Agreement.

 

11. Other Business Activities. You may be engaged or employed in any other business, trade, profession, or other activity while providing services to the Company, in which case you agree to abide by the terms of Section 6 and Section 7.

 

12. Intentionally Left Blank.

 

13. Assignment. You shall not assign any rights or delegate or subcontract any obligations under this Agreement without the Company's prior written consent. Any assignment in violation of the foregoing shall be deemed null and void. The Company may freely assign its rights and obligations under this Agreement at any time. Subject to the limits on assignment stated above, this Agreement will inure to the benefit of, be binding on, and be enforceable against each of the Parties and their respective successors and assigns.

 

14. Remedies. In the event you breach or threaten to breach Section 6 of this Agreement, you acknowledge and agree that money damages would not afford an adequate remedy and that the Company shall be entitled to seek a temporary or permanent injunction or other equitable relief restraining such breach or threatened breach from any court of competent jurisdiction without the necessity of showing any actual damages, and without the necessity of posting any bond or other security. Any equitable relief shall be in addition to, not in lieu of, legal remedies, monetary damages, or other available forms of relief.

 

15. Intentionally Left Blank.

 

16. Governing Law, Jurisdiction, and Venue. This Agreement and all related documents are governed by and construed in accordance with the laws of the State of California.

 

17. Miscellaneous.

 

17.1 You shall not export, directly or indirectly, any technical data acquired from the Company, or any products utilizing any such data, to any country in violation of any applicable export laws or regulations.

 

 
7

 

 

17.2 All notices, requests, consents, claims, demands, waivers, and other communications (each, a "Notice") shall be in writing and addressed to the Parties at the addresses set forth on the first page of this Agreement (or to such other address that may be designated by the receiving party from time to time in accordance with this Section). All Notices shall be delivered by personal delivery, nationally recognized overnight courier (with all fees prepaid), email, or certified or registered mail (in each case, return receipt requested, postage prepaid). Except as otherwise provided in this Agreement, a Notice is effective only if: (a) the receiving party has received the Notice; and (b) the party giving the Notice has complied with the requirements of this Section.

  

17.3 This Agreement, together with any other documents incorporated by reference and related exhibits and schedules, constitutes the sole and entire agreement of the Parties to this Agreement with respect to the subject matter contained herein, and supersedes all prior and contemporaneous understandings, agreements, representations, and warranties, both written and oral, with respect to such subject matter.

 

17.4 This Agreement may only be amended, modified, or supplemented by an agreement in writing signed by each party, and any of the terms thereof may be waived, only by a written document signed by each party to this Agreement or, in the case of waiver, by the party or parties waiving compliance.

 

17.5 If any term or provision of this Agreement is invalid, illegal, or unenforceable in any jurisdiction, such invalidity, illegality, or unenforceability shall not affect any other term or provision of this Agreement or invalidate or render unenforceable such term or provision in any other jurisdiction.

 

17.6 This Agreement may be executed in multiple counterparts and by electronic signature, each of which shall be deemed an original and all of which together shall constitute one instrument.

 

If this letter accurately sets forth our understanding, kindly execute the enclosed copy of this letter and return it to the undersigned.

 

Very truly yours,

 

Healthcare Business Resources Inc.

 

BY:

/s/ Drew Hall

 

Name:

Drew D. Hall

 

Title:

Chief Executive Officer

 

 

ACCEPTED AND AGREED:

 

/s/ Alex Bellehumeur

 

Name: Alex Bellehumeur

 

 

 
8

 

 

SCHEDULE 1

 

1. SERVICES: Provide consulting advice to the Company’s management team and board of directors, as a member of an “Advisory Committee”, in connection with various aspects of the Company’s strategic planning and business.

 

2. PAYMENT: $500 per month.

 

3. DELIVERABLES: None.

 

 
9

 

EX-101.SCH 3 hbr-20240105.xsd XBRL TAXONOMY EXTENSION SCHEMA 000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 hbr-20240105_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Entity Registrant Name Entity Central Index Key Document Type Amendment Flag Entity Emerging Growth Company Document Period End Date Entity Ex Transition Period Entity File Number Entity Incorporation State Country Code Entity Tax Identification Number Entity Address Address Line 1 Entity Address City Or Town Entity Address State Or Province Entity Address Postal Zip Code City Area Code Written Communications Soliciting Material Pre Commencement Tender Offer Pre Commencement Issuer Tender Offer Local Phone Number EX-101.CAL 5 hbr-20240105_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.PRE 6 hbr-20240105_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE EX-101.DEF 7 hbr-20240105_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE GRAPHIC 8 hbr_ex991img1.jpg begin 644 hbr_ex991img1.jpg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htm IDEA: XBRL DOCUMENT v3.23.4
Cover
Jan. 05, 2024
Cover [Abstract]  
Entity Registrant Name Healthcare Business Resources Inc.
Entity Central Index Key 0001796949
Document Type 8-K
Amendment Flag false
Entity Emerging Growth Company true
Document Period End Date Jan. 05, 2024
Entity Ex Transition Period false
Entity File Number 000-56214
Entity Incorporation State Country Code DE
Entity Tax Identification Number 84-3639946
Entity Address Address Line 1 1983 N Berra Blvd
Entity Address City Or Town Tooele
Entity Address State Or Province UT
Entity Address Postal Zip Code 84074
City Area Code 615
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Local Phone Number 856-5542
XML 10 hbr_8k_htm.xml IDEA: XBRL DOCUMENT 0001796949 2024-01-05 2024-01-05 iso4217:USD shares iso4217:USD shares 0001796949 false 8-K 2024-01-05 Healthcare Business Resources Inc. DE 000-56214 84-3639946 1983 N Berra Blvd Tooele UT 84074 615 856-5542 false false false false true false EXCEL 11 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 12 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 13 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 14 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.4 html 1 20 1 false 0 0 false 3 false false R1.htm 000001 - Document - Cover Sheet http://hbr.com/role/Cover Cover Cover 1 false false All Reports Book All Reports hbr-20240105.xsd hbr-20240105_cal.xml hbr-20240105_def.xml hbr-20240105_lab.xml hbr-20240105_pre.xml hbr_8k.htm http://xbrl.sec.gov/dei/2023 true true JSON 16 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "hbr_8k.htm": { "nsprefix": "hbr", "nsuri": "http://hbr.com/20240105", "dts": { "schema": { "local": [ "hbr-20240105.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/currency/2023/currency-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd", "https://xbrl.sec.gov/exch/2023/exch-2023.xsd", "https://xbrl.sec.gov/naics/2023/naics-2023.xsd", "https://xbrl.sec.gov/sic/2023/sic-2023.xsd", "https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd" ] }, "calculationLink": { "local": [ "hbr-20240105_cal.xml" ] }, "definitionLink": { "local": [ "hbr-20240105_def.xml" ] }, "labelLink": { "local": [ "hbr-20240105_lab.xml" ] }, "presentationLink": { "local": [ "hbr-20240105_pre.xml" ] }, "inline": { "local": [ "hbr_8k.htm" ] } }, "keyStandard": 20, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 21, "unitCount": 3, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 20 }, "report": { "R1": { "role": "http://hbr.com/role/Cover", "longName": "000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "From2024-01-05to2024-01-05", "name": "dei:EntityRegistrantName", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "strong", "p", "td", "tr", "tbody", "table", "body", "html" ], "reportCount": 1, "baseRef": "hbr_8k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-05to2024-01-05", "name": "dei:EntityRegistrantName", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "strong", "p", "td", "tr", "tbody", "table", "body", "html" ], "reportCount": 1, "baseRef": "hbr_8k.htm", "first": true, "unique": true } } }, "tag": { "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://hbr.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre Commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r2" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://hbr.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://hbr.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://hbr.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://hbr.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r0" ] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://hbr.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address Address Line 1", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://hbr.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r0" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://hbr.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r3" ] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://hbr.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r4" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://hbr.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation State Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://hbr.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://hbr.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r0" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://hbr.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://hbr.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address City Or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://hbr.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Ex Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r5" ] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://hbr.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre Commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r1" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://hbr.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://hbr.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address State Or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://hbr.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r0" ] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://hbr.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 17 0001654954-24-000764-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001654954-24-000764-xbrl.zip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end